EPISODE · Aug 24, 2020 · 39 MIN
Summer Sessions 7: Dr. Randall Schatzman & The New Fundraising Norm
from Business Of Biotech · host Matt Pillar
We love to hear from our listeners. Send us a message. Dr. Randy Schatzman, CEO at Bolt Biotherapeutics, discusses his company's adjustment to pandemic disruption on the fundraising trail. He walks us through the remote-fundraising strategy that landed Bolt's recent $93.5 million Series C financing round, and how the company is moving towards an IPO in spite of market, civil, and political tumult.Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: [email protected] Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Embed this episode
What this episode covers
We love to hear from our listeners. Send us a message. Dr. Randy Schatzman, CEO at Bolt Biotherapeutics, discusses his company's adjustment to pandemic disruption on the fundraising trail. He walks us through the remote-fundraising strategy that landed Bolt's recent $93.5 million Series C financing round, and how the company is moving towards an IPO in spite of market, civil, and political tumult. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of...
Ready to play
Summer Sessions 7: Dr. Randall Schatzman & The New Fundraising Norm
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.